KRAS and non-small cell lung carcinoma: However, the prognostic role of KRAS mutations is still unclear, although recent experience may suggest an unfavorable role compared to WT disease and when mutant KRAS NSCLC are associated with co-occurring mutations in advanced disease treated with chemo/chemoimmunotherapy (14, 15).